Your browser is no longer supported. Please, upgrade your browser.
ALBO Albireo Pharma, Inc. daily Stock Chart
Albireo Pharma, Inc.
Index- P/E- EPS (ttm)-5.89 Insider Own0.30% Shs Outstand14.13M Perf Week-13.27%
Market Cap394.96M Forward P/E- EPS next Y-6.33 Insider Trans- Shs Float11.62M Perf Month-1.74%
Income-77.50M PEG- EPS next Q-1.68 Inst Own77.70% Short Float2.02% Perf Quarter65.71%
Sales10.60M P/S37.26 EPS this Y-28.00% Inst Trans21.16% Short Ratio2.85 Perf Half Y5.36%
Book/sh8.03 P/B3.23 EPS next Y16.90% ROA-44.30% Target Price- Perf Year-17.17%
Cash/sh9.89 P/C2.62 EPS next 5Y- ROE-72.80% 52W Range11.26 - 32.38 Perf YTD2.08%
Dividend- P/FCF- EPS past 5Y18.10% ROI-61.60% 52W High-19.86% Beta1.90
Dividend %- Quick Ratio10.50 Sales past 5Y- Gross Margin- 52W Low130.46% ATR1.93
Employees55 Current Ratio10.50 Sales Q/Q150.00% Oper. Margin- RSI (14)46.82 Volatility8.03% 6.72%
OptionableYes Debt/Eq0.00 EPS Q/Q-60.50% Profit Margin- Rel Volume1.33 Prev Close26.21
ShortableYes LT Debt/Eq0.00 EarningsMay 07 BMO Payout- Avg Volume82.67K Price25.95
Recom1.60 SMA20-3.67% SMA501.62% SMA20018.32% Volume109,998 Change-0.99%
Jun-25-20Initiated Robert W. Baird Outperform $52
Feb-28-19Initiated H.C. Wainwright Buy $62
Apr-20-18Initiated Jefferies Buy $50
Nov-15-17Initiated ROTH Capital Buy $92
Jul-18-17Initiated Needham Buy $35
Jun-30-17Initiated Wedbush Outperform $58
Feb-16-17Initiated Ladenburg Thalmann Buy $40
Jul-01-20 10:23AM  
Jun-10-20 08:00AM  
Jun-09-20 07:30AM  
May-26-20 08:00AM  
May-12-20 06:29AM  
May-11-20 06:25AM  
May-08-20 03:30AM  
May-07-20 07:45AM  
May-03-20 08:34AM  
Apr-30-20 09:47AM  
Apr-07-20 08:30AM  
Mar-10-20 08:30AM  
Mar-04-20 05:05AM  
Mar-02-20 07:30AM  
Feb-29-20 02:52PM  
Feb-27-20 09:12AM  
Feb-26-20 08:30AM  
Feb-24-20 08:30AM  
Feb-03-20 04:01PM  
Jan-29-20 09:57PM  
Jan-23-20 08:00AM  
Dec-19-19 09:51PM  
Dec-17-19 05:06AM  
Nov-14-19 08:30AM  
Nov-06-19 02:51PM  
Nov-04-19 08:30AM  
Nov-02-19 09:26AM  
Nov-01-19 08:30PM  
Oct-30-19 08:00AM  
Oct-03-19 08:00AM  
Sep-30-19 09:23AM  
Sep-18-19 06:05AM  
Sep-03-19 08:30AM  
Aug-09-19 03:23AM  
Aug-08-19 07:30AM  
Aug-06-19 08:30AM  
Aug-01-19 08:30AM  
Jul-30-19 10:38AM  
Jul-09-19 04:05PM  
Jun-28-19 09:41PM  
Jun-20-19 09:24AM  
Jun-07-19 07:00AM  
May-29-19 07:30AM  
May-23-19 07:30AM  
May-09-19 07:23PM  
May-02-19 08:30AM  
Apr-13-19 07:30AM  
Apr-11-19 07:30AM  
Apr-01-19 07:30AM  
Mar-27-19 08:48AM  
Mar-21-19 08:30AM  
Mar-07-19 03:15PM  
Mar-04-19 08:30AM  
Feb-28-19 08:30AM  
Feb-27-19 08:30AM  
Feb-25-19 08:00AM  
Feb-07-19 12:38PM  
Jan-22-19 08:30AM  
Dec-23-18 03:36AM  
Dec-18-18 08:30AM  
Nov-13-18 07:00AM  
Nov-08-18 08:30AM  
Nov-06-18 08:30AM  
Nov-04-18 09:24PM  
Oct-26-18 09:00AM  
Oct-17-18 08:30AM  
Oct-15-18 08:30AM  
Oct-10-18 08:30AM  
Sep-25-18 07:30AM  
Sep-24-18 08:30AM  
Aug-29-18 08:30AM  
Aug-08-18 08:30AM  
Aug-07-18 07:30AM  
Aug-02-18 04:01PM  
Jul-31-18 07:45AM  
Jul-25-18 08:30AM  
Jun-25-18 08:30AM  
Jun-18-18 08:30AM  
Jun-12-18 08:30AM  
Jun-08-18 09:00AM  
May-29-18 08:00AM  
May-24-18 07:20AM  
May-17-18 07:30AM  
May-16-18 08:30AM  
May-09-18 08:00AM  
Apr-30-18 08:00AM  
Apr-19-18 08:00AM  
Apr-14-18 08:00AM  
Apr-03-18 08:00AM  
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis; and A3384 for the treatment of gastrointestinal diseases. It has a license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stephenson PamelaChief Commercial OfficerJun 25Sale30.7939712,22422,818Jun 26 05:02 PM
Horn Patrick TaylorChief Medical OfficerApr 22Sale17.64921,6234,465Apr 24 05:22 PM
Duncan JasonChief Legal Officer and GCApr 22Sale17.68921,6274,461Apr 24 05:20 PM
Harford Simon N.R.CFO and TreasurerApr 13Sale16.52971,6024,798Apr 13 08:57 PM
Stephenson PamelaChief Commercial OfficerMar 25Sale17.601,78531,41623,215Mar 25 04:43 PM
PERCEPTIVE ADVISORS LLC10% OwnerFeb 03Buy21.00255,8095,371,9891,960,139Feb 04 08:00 AM
Horn Patrick TaylorChief Medical OfficerJan 22Sale24.2944310,7604,557Jan 23 07:28 PM
Duncan JasonChief Legal Officer and GCJan 22Sale23.9744710,7154,553Jan 23 07:22 PM
Harford Simon N.R.CFO and TreasurerJan 10Sale27.201052,8564,895Jan 14 04:18 PM